Alberta is strengthening its position in Canada’s biotechnology landscape through the continued development of industrial expertise, advanced manufacturing infrastructure, world-class research and a growing community of companies scaling beyond the province.

Alberta is home to the Canadian Critical Drug Initiative (CCDI), which is creating an integrated research, commercialization and manufacturing cluster to support the development and production of life-saving innovations in Canada. Central to this is the Critical Medicines Production Centre (CMPC), a new 83,000+ square-foot manufacturing facility scheduled to open next year at the Life Sciences Campus in Edmonton. The facility will be the largest of its kind in Canada and provide flexible manufacturing capabilities helping to strengthen Canada’s sovereignty while providing life sciences innovators with the infrastructure required to bring life-saving products to market and scale production.

The Alberta Industrial Heartland is home to one of Canada’s largest concentrations of petrochemical and chemical manufacturing. Petrochemical-derived chemicals serve as important starting materials and building blocks across pharmaceutical manufacturing and health technologies. By connecting Alberta’s established chemical expertise and supply chains with its growing life sciences manufacturing capabilities, the province has an opportunity to capture more of the pharmaceutical value chain domestically and build a more integrated Canadian supply chain.

Alberta has also demonstrated an ability to attract and retain globally recognized scientific talent. Nobel Laureate Sir Michael Houghton is among the researchers who have built and scaled significant research programs in Edmonton, contributing to a concentration of expertise in areas including virology, vaccines and infectious disease.This combination of scientific leadership, research institutions and commercialization infrastructure is fostering an environment where discoveries can move beyond the laboratory, attracting global attention.

Alberta innovation is increasingly making its mark beyond Canada.Companies like Voyageur Pharmaceuticals and Future Fields are reaching major commercialization milestones and expanding internationally. Voyager is building North America’s first secure, vertically integrated domestic supply of contrast media, while Future Fields is pioneering protein production using genetically engineered fruit flies.Their growth demonstrates the global potential of technologies developed and scaled in Alberta.

This momentum is accelerating, supporting Canada’s journey toward a more resilient and sovereign life sciences sector while creating more opportunities for homegrown innovations to scale. By advancing Canada-first initiatives and continuing to invest in infrastructure, talent and industry, Alberta is creating the conditions to attract new investment, expertise and partnerships that will drive future growth.